Dataconomy
  • News
    • Artificial Intelligence
    • Cybersecurity
    • DeFi & Blockchain
    • Finance
    • Gaming
    • Startups
    • Tech
  • Industry
  • Research
  • Resources
    • Articles
    • Guides
    • Case Studies
    • Glossary
    • Whitepapers
  • Newsletter
  • + More
    • Conversations
    • Events
    • About
      • About
      • Contact
      • Imprint
      • Legal & Privacy
      • Partner With Us
Subscribe
No Result
View All Result
  • AI
  • Tech
  • Cybersecurity
  • Finance
  • DeFi & Blockchain
  • Startups
  • Gaming
Dataconomy
  • News
    • Artificial Intelligence
    • Cybersecurity
    • DeFi & Blockchain
    • Finance
    • Gaming
    • Startups
    • Tech
  • Industry
  • Research
  • Resources
    • Articles
    • Guides
    • Case Studies
    • Glossary
    • Whitepapers
  • Newsletter
  • + More
    • Conversations
    • Events
    • About
      • About
      • Contact
      • Imprint
      • Legal & Privacy
      • Partner With Us
Subscribe
No Result
View All Result
Dataconomy
No Result
View All Result

OpenAI and xAI talking AI drug evaluation with FDA

Discussions reportedly centered on how AI could optimize some of the more time-consuming stages towards the end of the drug evaluation timeline.

byKerem Gülen
May 8, 2025
in Industry

OpenAI has met with officials from the U.S. Food and Drug Administration (FDA) to discuss using AI to speed up drug evaluations, according to a report by Wired. The discussions centered around a project called cderGPT, an AI tool designed for the Center for Drug Evaluation (CDE), which regulates over-the-counter and prescription drugs in the U.S.

Associates from Elon Musk’s xAI were also reportedly part of the talks. OpenAI’s collaboration with the FDA aims to accelerate the drug development process, which often takes over a decade to complete. AI is seen as a potential tool to make some of the slower steps in drug development more efficient, particularly toward the end of the timeline.

The use of AI in drug development has been touted as a potential accelerant, but questions remain about how to control for the unreliability of AI models. The cderGPT project is part of a broader effort to leverage AI to streamline the notoriously slow drug evaluation process.

Stay Ahead of the Curve!

Don't miss out on the latest insights, trends, and analysis in the world of data, technology, and startups. Subscribe to our newsletter and get exclusive content delivered straight to your inbox.


Featured image credit

Tags: openAIxai

Related Posts

Qualcomm (QCOM) stock soars as company challenges Nvidia with new AI data center chips

Qualcomm (QCOM) stock soars as company challenges Nvidia with new AI data center chips

October 27, 2025
X loses its ad chief as John Nitti steps down after 10 months

X loses its ad chief as John Nitti steps down after 10 months

October 27, 2025
Microsoft sued by Australia over Copilot pricing practices

Microsoft sued by Australia over Copilot pricing practices

October 27, 2025
TikTok sale finalized as Trump and Xi prepare to close deal this week

TikTok sale finalized as Trump and Xi prepare to close deal this week

October 27, 2025
EU says Facebook and Instagram violate the Digital Services Act

EU says Facebook and Instagram violate the Digital Services Act

October 24, 2025
Europe’s biggest aerospace players unite to build a SpaceX rival

Europe’s biggest aerospace players unite to build a SpaceX rival

October 24, 2025

LATEST NEWS

OpenAI adds scheduling powers to ChatGPT with new Tasks feature

Instagram adds watch history for Reels on Android and iOS

Huawei: Quad-foldable phone is possible in 2026

Watch: SpaceX launches 84 more Starlink satellites in three Falcon 9 missions over 4 days

Mistral AI takes on Google with enterprise AI Studio

Gemini can now generate full presentations from text or files

Dataconomy

COPYRIGHT © DATACONOMY MEDIA GMBH, ALL RIGHTS RESERVED.

  • About
  • Imprint
  • Contact
  • Legal & Privacy

Follow Us

  • News
    • Artificial Intelligence
    • Cybersecurity
    • DeFi & Blockchain
    • Finance
    • Gaming
    • Startups
    • Tech
  • Industry
  • Research
  • Resources
    • Articles
    • Guides
    • Case Studies
    • Glossary
    • Whitepapers
  • Newsletter
  • + More
    • Conversations
    • Events
    • About
      • About
      • Contact
      • Imprint
      • Legal & Privacy
      • Partner With Us
No Result
View All Result
Subscribe

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy Policy.